Lawrence Biegelsen

Shockwave Medical Inc (NSDQ: SWAV) first-quarter FY21 sales more than double to $31.9 million beating the Wall Street consensus of $29.9 million. The growth was primarily driven by the launch of the coronary product, Shockwave C, in the U.S. in February and increased adoption of...